Biogen jettisons AMD drug, providing Catalyst for ex-partner's hunt for strategic alternatives

Biogen has dumped the dry age-related macular degeneration (AMD) candidate it licensed from Catalyst Biosciences, giving its onetime partner full control of another asset as it weighs up strategic alternatives.